C4 Therapeutics (NASDAQ: CCCC) revenue
C4 Therapeutics reported revenue of $35.9m for fiscal 2025, 1.0% more than in fiscal 2024 ($35.6m). Since fiscal 2021 its revenue has fallen by 21.5%, an average decline of 5.9% a year.
C4 Therapeutics has grown its revenue for 2 years in a row, and its best year of the last 5 was fiscal 2021. The biggest drop was in fiscal 2023, −33.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $35.9m | +1.0% | −$115.2m | −320.5% |
| 2024 | $35.6m | +71.4% | −$119.6m | −336.1% |
| 2023 | $20.8m | −33.3% | −$139.0m | −669.8% |
| 2022 | $31.1m | −32.1% | −$129.5m | −416.6% |
| 2021 | $45.8m | — | −$82.1m | −179.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
C4 Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, C4 Therapeutics ranks 343rd of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; C4 Therapeutics, 1.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 341st | Utah Medical Products | $38.5m | −5.8% |
| 342nd | ClearPoint Neuro | $37.0m | 17.8% |
| 343rd | C4 Therapeutics | $35.9m | 1.0% |
| 344th | Senseonics | $35.3m | 56.9% |
| 345th | X4 Pharmaceuticals | $35.1m | 1,250.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of C4 Therapeutics
- How much revenue did C4 Therapeutics make in fiscal 2025?
- C4 Therapeutics reported revenue of $35.9m for fiscal 2025, compared with $35.6m in fiscal 2024.
- How much has the revenue of C4 Therapeutics fallen?
- Between fiscal 2021 and fiscal 2025 it went from $45.8m to $35.9m: 21.5% less, an average decline of 5.9% a year.
- What was the best year for revenue at C4 Therapeutics?
- Of its last 5 fiscal years, fiscal 2021, with $45.8m.
- Where does C4 Therapeutics rank in its sector by revenue?
- It ranks 343rd of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for C4 Therapeutics come from?
- From the annual report (Form 10-K) that C4 Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that C4 Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on C4 Therapeutics: the C4 Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.